Pitavastatin is a modern statin for the correction of dyslipidemia and the risk of cardiovascular complications

Authors

  • A. Catapano President of the European Society for Atherosclerosis
  • V. V. Kukharchuk Russian Cardiology Research Complex
  • I. V. Sergienko Russian Cardiology Research Complex
  • M. V. Ezhov Russian Cardiology Research Complex
  • A. V. Susekov Department of Clinical Pharmacology and Therapy of Russian Medical Academy Continuous Professional Education
  • S. R. Gilyarevsky Department of Clinical Pharmacology and Therapy of Russian Medical Academy Continuous Professional Education
  • S. Yu. Martsevich Research Institute of Preventive Medicine
  • I. I. Chukaeva Department of Polyclinic Therapy of the Therapeutic faculty Pirogov Russian National Research Medical University

Keywords:

Pitavastatin, modern statin, correction of dyslipidemia and the risk of cardiovascular complications, Resolution of the expert council

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide, and coronary artery disease (CHD) is the main contributor to mortality from diseases of the circulatory system in developed countries. About 4 million people die from CVD in Europe every year, of whom the majority are women (2.2 million, 55%), although under the age of 65 CVD mortality is higher in men (490,000 versus 193,000)

Downloads

Download data is not yet available.

Downloads

Published

2017-06-29

How to Cite

Catapano A., Kukharchuk V. V., Sergienko I. V., Ezhov M. V., Susekov A. V., Gilyarevsky S. R., Martsevich S. Y., Chukaeva I. I. Pitavastatin is a modern statin for the correction of dyslipidemia and the risk of cardiovascular complications // The Journal of Atherosclerosis and Dyslipidemias. 2017. VOL. № 2 (27). PP. 104–107.

Issue

No. 2 (27) (2017)

Section

Resolution

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 > >>